561 related articles for article (PubMed ID: 17868689)
21. [Primary study on establishment of namalwa 12/MTX resistant cell strain and its mechanism].
Chen J; Gu LJ; Ying DM; Shen M; Wu HJ
Ai Zheng; 2002 Dec; 21(12):1335-40. PubMed ID: 12520743
[TBL] [Abstract][Full Text] [Related]
22. Methotrexate resistance of mouse dihydrofolate reductase: effect of substitution of phenylalanine-31 by serine or tryptophan.
Evenson DA; Adams J; McIvor RS; Wagner CR
J Med Chem; 1996 Apr; 39(9):1763-6. PubMed ID: 8627598
[TBL] [Abstract][Full Text] [Related]
23. Molecular mechanisms of resistance to antifolates, a review.
Banerjee D; Ercikan-Abali E; Waltham M; Schnieders B; Hochhauser D; Li WW; Fan J; Gorlick R; Goker E; Bertino JR
Acta Biochim Pol; 1995; 42(4):457-64. PubMed ID: 8852336
[TBL] [Abstract][Full Text] [Related]
24. In Silico Study Identified Methotrexate Analog as Potential Inhibitor of Drug Resistant Human Dihydrofolate Reductase for Cancer Therapeutics.
Rana RM; Rampogu S; Abid NB; Zeb A; Parate S; Lee G; Yoon S; Kim Y; Kim D; Lee KW
Molecules; 2020 Jul; 25(15):. PubMed ID: 32752079
[TBL] [Abstract][Full Text] [Related]
25. Methotrexate selection of long-term culture initiating cells following transduction of CD34(+) cells with a retrovirus containing a mutated human dihydrofolate reductase gene.
Takebe N; Xu LC; MacKenzie KL; Bertino JR; Moore MA
Cancer Gene Ther; 2002 Mar; 9(3):308-20. PubMed ID: 11896448
[TBL] [Abstract][Full Text] [Related]
26. Detection of long-lived bound water molecules in complexes of human dihydrofolate reductase with methotrexate and NADPH.
Meiering EM; Wagner G
J Mol Biol; 1995 Mar; 247(2):294-308. PubMed ID: 7707376
[TBL] [Abstract][Full Text] [Related]
27. [Double-mutant dihydrofolate reductase gene transfection into bone marrow cells protects mice from chemotherapy].
Gao HD; Lu P; Lu Y; Pang K; Xu HM; Wang SB; Chen JQ; Zhao SC
Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):583-5. PubMed ID: 17236551
[TBL] [Abstract][Full Text] [Related]
28. Methotrexate resistance conferred by transplantation of drug-resistant transgenic marrow cells fractionated bycounterflow elutriation.
James R; May C; Diers M; Wagner J; McIvor R
Bone Marrow Transplant; 1999 Oct; 24(8):815-21. PubMed ID: 10516690
[TBL] [Abstract][Full Text] [Related]
29. Active site-directed double mutants of dihydrofolate reductase.
Ercikan-Abali EA; Mineishi S; Tong Y; Nakahara S; Waltham MC; Banerjee D; Chen W; Sadelain M; Bertino JR
Cancer Res; 1996 Sep; 56(18):4142-5. PubMed ID: 8797582
[TBL] [Abstract][Full Text] [Related]
30. [Mechanisms of development of resistance to methotrexate in choriocarcinoma cells].
Sakai K
Hokkaido Igaku Zasshi; 1986 Sep; 61(5):649-61. PubMed ID: 3781466
[TBL] [Abstract][Full Text] [Related]
31. Transgenic mice expressing the tyr22 variant of murine DHFR: protection of transgenic marrow transplant recipients from lethal doses of methotrexate.
James RI; May C; Vagt MD; Studebaker R; McIvor RS
Exp Hematol; 1997 Nov; 25(12):1286-95. PubMed ID: 9357973
[TBL] [Abstract][Full Text] [Related]
32. Effect of methotrexate on dihydrofolate reductase activity in methotrexate-resistant human KB cells.
Domin BA; Grill SP; Bastow KF; Cheng YC
Mol Pharmacol; 1982 Mar; 21(2):478-82. PubMed ID: 7099148
[TBL] [Abstract][Full Text] [Related]
33. Transfection of DHFR- and DHFR+ mammalian cells using methotrexate-resistant mutants of mouse dihydrofolate reductase.
Thillet J; Pictet R
FEBS Lett; 1990 Sep; 269(2):450-3. PubMed ID: 2401371
[TBL] [Abstract][Full Text] [Related]
34. Variants of human dihydrofolate reductase with substitutions at leucine-22: effect on catalytic and inhibitor binding properties.
Ercikan-Abali EA; Waltham MC; Dicker AP; Schweitzer BI; Gritsman H; Banerjee D; Bertino JR
Mol Pharmacol; 1996 Mar; 49(3):430-7. PubMed ID: 8643082
[TBL] [Abstract][Full Text] [Related]
35. Dihydrofolate reductase mutant with exceptional resistance to methotrexate but not to trimetrexate.
Pineda P; Kanter A; McIvor RS; Benkovic SJ; Rosowsky A; Wagner CR
J Med Chem; 2003 Jul; 46(14):2816-8. PubMed ID: 12825924
[TBL] [Abstract][Full Text] [Related]
36. Comparison of methotrexate resistance conferred by a mutated dihydrofolate reductase (DHFR) cDNA in two different retroviral vectors.
Takebe N; Nakahara S; Zhao SC; Adhikari D; Ural AU; Iwamoto M; Banerjee D; Bertino JR
Cancer Gene Ther; 2000 Jun; 7(6):910-9. PubMed ID: 10880023
[TBL] [Abstract][Full Text] [Related]
37. Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase.
Jolivet J; Chabner BA
J Clin Invest; 1983 Sep; 72(3):773-8. PubMed ID: 6193143
[TBL] [Abstract][Full Text] [Related]
38. Evolution of methotrexate resistance of human acute lymphoblastic leukemia cells in vitro.
Ohnuma T; Lo RJ; Scanlon KJ; Kamen BA; Ohnoshi T; Wolman SR; Holland JF
Cancer Res; 1985 Apr; 45(4):1815-22. PubMed ID: 3856477
[TBL] [Abstract][Full Text] [Related]
39. Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide.
Lindgren M; Rosenthal-Aizman K; Saar K; Eiríksdóttir E; Jiang Y; Sassian M; Ostlund P; Hällbrink M; Langel U
Biochem Pharmacol; 2006 Feb; 71(4):416-25. PubMed ID: 16376307
[TBL] [Abstract][Full Text] [Related]
40. Defining the binding site of homotetrameric R67 dihydrofolate reductase and correlating binding enthalpy with catalysis.
Strader MB; Chopra S; Jackson M; Smiley RD; Stinnett L; Wu J; Howell EE
Biochemistry; 2004 Jun; 43(23):7403-12. PubMed ID: 15182183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
